Corvalol Darnytsia drops, oral solution, bottle of 40 ml

Corvalol Darnytsia has a sedative and antispasmodic effect, which is due to its components.

Thus, the reflex sedative effect occurs due to the ethyl ester of α-bromisovaleric acid. In addition, this substance has antispasmodic properties.

Phenobarbital inhibits the reticular formation, which activates the cerebral cortex. This leads to the development of a sedative effect, a decrease in nervous tension, or a hypnotic effect (depending on the dose).

As a result of taking the drug, the activating effect on the vascular center, peripheral vascular system, and coronary vessels of the heart weakens.

The irritating effect of menthol and its esters, contained in peppermint oil, on the cold receptors of the oral mucosa contributes to:

• reflex vasodilation of cerebral vessels and heart vessels;
• relief of smooth muscle spasm;
• the occurrence of a sedative effect.

Peppermint oil also causes:

• antispasmodic effect;
• slight choleretic effect;
• disinfecting properties;
• increased intestinal peristalsis;
• elimination of excessive gas accumulation in the digestive tract.

Pharmacokinetics. After oral administration, the beginning of absorption occurs already in the regio sublingualis. The components of the drug are highly bioavailable – about 60-80%. When used sublingually or on a sugar cube, the development of action occurs most quickly – 5-10 minutes after administration. The effect increases after 15-45 minutes and lasts 3-6 hours. The period of activity is reduced in patients who have previously used barbiturates. This is due to the induction of metabolic enzymes in the liver by drugs of this group. Patients with cirrhotic liver changes and elderly patients are characterized by a decrease in hepatic metabolism of the drug. This leads to an increase in T _½ and requires a corresponding correction (reduction) of the dose of the drug, as well as an increase in the time period between its administrations.

Per os 15-30 drops with water or on a piece of sugar 2-3 times a day. Food intake does not affect the intake of the drug. A single dose can be increased to 40-50 drops in case of a pronounced increase in heart rate and spasm of the coronary arteries.

The duration of use is determined by the doctor (depending on the tolerability of the drug and its clinical effectiveness).

• Corvalol Darnytsia is generally well tolerated.

Side effects, possible in some cases, are as follows:

• Digestive system: constipation, feeling of heaviness in the epigastric region.

Long-term use of the drug may cause liver dysfunction, episodes of nausea or vomiting;

• nervous system: dizziness (mild), impaired coordination of movements, ataxia, nystagmus, weakness, fatigue, slowed reaction time, hallucinations, headache, cognitive dysfunction, confusion, drowsiness, paradoxical excitement, decreased concentration;
• immune system: hypersensitivity reactions (including angioedema);
• skin and mucous membranes: allergic reactions (including skin rash, itching, urticaria), as well as Lyell’s and Stevens-Johnson syndromes (especially possible in the first weeks of treatment);
• Blood system: anemia, thrombocytopenia, agranulocytosis;
• respiratory system: difficulty breathing;
• cardiovascular system: decreased heart rate, arterial hypotension;
• musculoskeletal system: risk of impaired bone formation (occurs with long-term use of phenobarbital as part of medications).

A prolonged period of intake may lead to the development of symptoms of bromine intoxication.

If the dose is reduced or the drug is discontinued, these effects disappear.

Drowsiness and dizziness, coordination disorders, and decreased psychomotor speed during the use of the drug may be caused by its components – phenobarbital and ethanol. Therefore, activities that require quick reactions and concentration of attention are not recommended during the use of the drug.

The drug can cause drug dependence if taken for a long period of time.

The ethanol content in the preparation is 56 vol.%.

Do not combine with alcohol.

Caution should be exercised in patients with epilepsy, as well as in patients with liver disease.

The effect of the drug is enhanced when combined with centrally acting drugs (depressant type). Valproates and ethanol also enhance the effect of Corvalol Darnytsia.

Induction of liver enzymes by phenobarbital may lead to a decrease in T½ _of drugs that are biotransformed in the liver.

Taking phenobarbital leads to an increase in the effect of painkillers and local anesthetics.

An increase in the duration of action of phenobarbital occurs against the background of the use of MAO inhibitors.

Concomitant use with rifampicin reduces the activity of phenobarbital.

The drug enhances the toxic properties of methotrexate. Simultaneous administration with zidovudine leads to increased toxicity of both zidovudine and methotrexate.

Long-term use in combination with nonsteroidal anti-inflammatory drugs leads to the risk of stomach ulcers, including those complicated by bleeding. Concomitant use with gold preparations increases the risk of kidney damage.

Accumulation of the drug components in the body is possible as a result of its prolonged or frequent use. With an increase in the period of use, psychomotor agitation, addiction and withdrawal syndrome may develop.

It is manifested by depression of CNS functions (including coma), respiratory suppression (including respiratory arrest), suppression of cardiovascular activity (including cardiac arrhythmias), decreased blood pressure (including mild collapse), decreased body temperature, decreased urine production and excretion, nausea, and weakness.

At a temperature ≤25 °C in the original packaging. Do not freeze.